DURECT Corporation DRRX · Stock Open DURECT Corporation in new tab
DURECT Corporation Analysis (DRRX)
Is DURECT Corporation a good investment? DURECT Corporation (DRRX) is currently trading at 1.91 USD.
Investor FAQ
Does DURECT Corporation pay a dividend?
No, it does not currently pay a dividend.
What asset class is DURECT Corporation?
DURECT Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 6, 2022 | 1:10 |
Community Discussion